Back to search results

Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)

Abroad (travel likely)RecruitingPHASE1

Conditions

Lymphangioleiomyomatosis (LAM) · Lymphangioleiomyomatosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Columbia University Irving Medical Center, New York, New York, United States

    Contact: Study coordinator (Katarina Koumbourlis) · kk3922@cumc.columbia.edu · 212-305-3745
    Contact: Study coordinator (Sabrina Palumbo, BS) · sp4461@cumc.columbia.edu · 212-305-3745
    Contact: Principal Investigator (Jeanine D'Armiento, MD, PhD)
    Monica Goldklang, MD (Sub-investigator)

  • Medical University of South Carolina, Charleston, South Carolina, United States

    Contact: Study coordinator (Seth Polk) · polkse@musc.edu · 7573341517
    Contact: Principal Investigator (Charlie Strange, MD)
Study leads

  • Jeanine D'Armiento, MD, PhD

    Principal Investigator

    Columbia University

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)